Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation

被引：12

作者：

Lange, T

Bumm, T

Mueller, M

Otto, S

Al-Ali, HK

Grommisch, L

Musiol, S

Franke, C

Krahl, R

Niederwieser, D

Deininger, M

机构：

[1] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Inst Canc, Portland, OR 97239 USA

[2] Univ Leipzig, Dept Hematol & Oncol, D-7010 Leipzig, Germany

[3] Univ Leipzig, Dept Clin Chem & Mol Diagnost, D-7010 Leipzig, Germany

来源：

LEUKEMIA | 2005年 / 19卷 / 07期

关键词：

D O I：

10.1038/sj.leu.2403752

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1262 / 1265

页数：4

共 8 条

[1] The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease [J].

Bose, S ;

Deininger, M ;

Gora-Tybor, J ;

Goldman, JM ;

Melo, JV .

BLOOD, 1998, 92 (09) :3362-3367

[2] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[3] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[4]

Lange T, 2004, HAEMATOLOGICA, V89, P49

[5] Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α [J].

Merx, K ;

Müller, MC ;

Kreil, S ;

Lahaye, T ;

Paschka, P ;

Schoch, C ;

Weisser, A ;

Kuhn, C ;

Berger, U ;

Gschaidmeier, H ;

Hehlmann, R ;

Hochhaus, A .

LEUKEMIA, 2002, 16 (09) :1579-1583

[6] POLYMERASE CHAIN-REACTION DETECTION OF THE BCR-ABL FUSION TRANSCRIPT AFTER ALLOGENEIC MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA - RESULTS AND IMPLICATIONS IN 346 PATIENTS [J].

RADICH, JP ;

GEHLY, G ;

GOOLEY, T ;

BRYANT, E ;

CLIFT, RA ;

COLLINS, S ;

EDMANDS, S ;

KIRK, J ;

LEE, A ;

KESSLER, P ;

SCHOCH, G ;

BUCKNER, CD ;

SULLIVAN, KM ;

APPELBAUM, FR ;

THOMAS, ED .

BLOOD, 1995, 85 (09) :2632-2638

[7] Molecular response to imatinib in late chronic-phase chronic myeloid leukemia [J].

Rosti, G ;

Martinelli, G ;

Bassi, S ;

Amabile, M ;

Trabacchi, E ;

Giannini, B ;

Cilloni, D ;

Izzo, B ;

De Vivo, A ;

Testoni, N ;

Cambrin, GR ;

Bonifazi, F ;

Soverini, S ;

Luatti, S ;

Gottardi, E ;

Alberti, D ;

Pane, F ;

Salvatore, F ;

Saglio, G ;

Baccarani, M .

BLOOD, 2004, 103 (06) :2284-2290

[8] Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (ST1571) [J].

Scheuring, UJ ;

Pfeifer, H ;

Wassmann, B ;

Brück, P ;

Atta, J ;

Petershofen, EK ;

Gehrke, B ;

Gschaidmeier, H ;

Hoelzer, D ;

Ottmann, OG .

BLOOD, 2003, 101 (01) :85-90

← 1 →